CCD,

That part is not new. We already knew that the CKD subgroup (baseline eGFR <60) of BETonMACE responded to apabetalone with a huge MACE reduction. What is not known to us lay folk is how many of the CKD patients were on SGLT2i and other related clinical stats of the CKD subgroup of BETonMACE. From the description of BETonMACE2, most will be on SGLT2i and there will be a greater proportion of CKD patients in BETonMACE2. 

Thus far management has discussed SGLT2i and CKD effects separately. Are they related? Are the observations of the CKD subgroup driven by SGLT2i, or possibly vice versa?

BDAZ